EXP2SL: A Machine Learning Framework for Cell-Line-Specific Synthetic Lethality Prediction
Synthetic lethality (SL), an important type of genetic interaction, can provide useful insight into the target identification process for the development of anticancer therapeutics. Although several well-established SL gene pairs have been verified to be conserved in humans, most SL interactions rem...
Saved in:
Published in | Frontiers in pharmacology Vol. 11; p. 112 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
Frontiers Media S.A
28.02.2020
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Synthetic lethality (SL), an important type of genetic interaction, can provide useful insight into the target identification process for the development of anticancer therapeutics. Although several well-established SL gene pairs have been verified to be conserved in humans, most SL interactions remain cell-line specific. Here, we demonstrated that the cell-line-specific gene expression profiles derived from the shRNA perturbation experiments performed in the LINCS L1000 project can provide useful features for predicting SL interactions in human. In this paper, we developed a semi-supervised neural network-based method called EXP2SL to accurately identify SL interactions from the L1000 gene expression profiles. Through a systematic evaluation on the SL datasets of three different cell lines, we demonstrated that our model achieved better performance than the baseline methods and verified the effectiveness of using the L1000 gene expression features and the semi-supervise training technique in SL prediction. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Edited by: Alex Zhavoronkov, Biogerontology Research Foundation, United Kingdom Reviewed by: Feng ZHU, Zhejiang University, China; Vasileios Stathias, University of Miami, United States; Qi Zhao, Shenyang Aerospace University, China; Jihye Kim, University of Colorado Anschutz Medical Campus, United States; Bhaskar Roy, Beijing Genomics Institute (BGI), China These authors have contributed equally to this work This article was submitted to Translational Pharmacology, a section of the journal Frontiers in Pharmacology |
ISSN: | 1663-9812 1663-9812 |
DOI: | 10.3389/fphar.2020.00112 |